Tokyo Tape
Sign in
← Toho Holdings

Quarterly report · Q1

8129.TEDINET S100RNXE
Period2023-04-01 → 2023-06-30
Filed2023-08-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 34
MetricValuePeriodScopeSource row
Revenue¥351.2bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥1.39T2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥324.3bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income¥1.9bn2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥2.3bn2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income¥2.5bn2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥19.2bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.1bn2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥2.5bn2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥3.0bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥1.5bn2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥13.6bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.1bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥1.5bn2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥2.1bn2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥734.5bnat 2023-06-30Cons.Assets
Total assets¥715.3bnat 2023-03-31Cons.Assets
Total assets¥710.1bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥493.4bnat 2023-06-30Cons.Liabilities
Total liabilities¥472.4bnat 2023-03-31Cons.Liabilities
Net assets / equity¥241.1bnat 2023-06-30Cons.Net assets
Net assets / equity¥242.9bnat 2023-03-31Cons.Net assets
Net assets / equity¥243.7bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥92.8bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥86.2bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥23.072023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥196.72022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥29.222022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥21.122023-04-01 → 2023-06-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥180.672022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥26.862022-04-01 → 2022-06-30Cons.Diluted earnings per share (5-year summary)
Equity ratio32.8%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio33.9%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio34.3%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥14.9bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥14.9bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥810m
jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segmentrevenue2023-04-01 → 2023-06-30¥22.8bn
jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2023-04-01 → 2023-06-30¥22.8bn
jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥1m
jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2023-04-01 → 2023-06-30¥112m
jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2023-04-01 → 2023-06-30¥2.7bn
jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2023-04-01 → 2023-06-30¥608m
jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥2.0bn
jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2023-04-01 → 2023-06-30¥293m
jpcrp040300-q1r_E02608-000Medical Products Retailreportable segmentrevenue2023-04-01 → 2023-06-30¥339.1bn
jpcrp040300-q1r_E02608-000Medical Products Retailreportable segmentrevenue external2023-04-01 → 2023-06-30¥326.6bn
jpcrp040300-q1r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥12.5bn
jpcrp040300-q1r_E02608-000Medical Products Retailreportable segmentsegment profit2023-04-01 → 2023-06-30¥2.2bn
jpcrp040300-q1r_E02608-000Other Related Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥1.5bn
jpcrp040300-q1r_E02608-000Other Related Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥1.1bn
jpcrp040300-q1r_E02608-000Other Related Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥338m
jpcrp040300-q1r_E02608-000Other Related Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥35m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-06-30¥366.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-06-30¥351.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-06-30¥14.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-06-30¥2.7bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥14.6bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥14.6bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥401m
jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segmentrevenue2022-04-01 → 2022-06-30¥22.2bn
jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2022-04-01 → 2022-06-30¥22.2bn
jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2022-04-01 → 2022-06-30¥133m
jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2022-04-01 → 2022-06-30¥2.5bn
jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2022-04-01 → 2022-06-30¥612m
jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥1.9bn
jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2022-04-01 → 2022-06-30¥288m
jpcrp040300-q1r_E02608-000Medical Products Retailreportable segmentrevenue2022-04-01 → 2022-06-30¥312.7bn
jpcrp040300-q1r_E02608-000Medical Products Retailreportable segmentrevenue external2022-04-01 → 2022-06-30¥300.3bn
jpcrp040300-q1r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥12.4bn
jpcrp040300-q1r_E02608-000Medical Products Retailreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.2bn
jpcrp040300-q1r_E02608-000Other Related Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥1.5bn
jpcrp040300-q1r_E02608-000Other Related Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥1.2bn
jpcrp040300-q1r_E02608-000Other Related Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥356m
jpcrp040300-q1r_E02608-000Other Related Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥94m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥338.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥324.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥14.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥2.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 417
ItemContextValueUnit
Short term loans payablePrior1YearInstant9800000000JPY
Short term loans payableCurrentQuarterInstant9218000000JPY
Current portion of bondsPrior1YearInstant20003000000JPY
Current portion of bondsCurrentQuarterInstant－JPY
Income taxes payablePrior1YearInstant5152000000JPY
Income taxes payableCurrentQuarterInstant1635000000JPY
Provision for bonusesPrior1YearInstant3214000000JPY
Provision for bonusesCurrentQuarterInstant4834000000JPY
Provision for directors bonusesPrior1YearInstant42000000JPY
Provision for directors bonusesCurrentQuarterInstant10000000JPY
Asset retirement obligations clPrior1YearInstant40000000JPY
Asset retirement obligations clCurrentQuarterInstant178000000JPY
Other clPrior1YearInstant16794000000JPY
Other clCurrentQuarterInstant18483000000JPY
Current liabilitiesPrior1YearInstant440188000000JPY
Current liabilitiesCurrentQuarterInstant437838000000JPY
Bonds payablePrior1YearInstant－JPY
Bonds payableCurrentQuarterInstant22109000000JPY
Long term loans payablePrior1YearInstant6472000000JPY
Long term loans payableCurrentQuarterInstant6372000000JPY
Net defined benefit liabilityPrior1YearInstant2508000000JPY
Net defined benefit liabilityCurrentQuarterInstant2505000000JPY
Asset retirement obligations nclPrior1YearInstant2747000000JPY
Asset retirement obligations nclCurrentQuarterInstant2641000000JPY
Provision for loss on anti monopoly act nclPrior1YearInstant4849000000JPY
Provision for loss on anti monopoly act nclCurrentQuarterInstant4849000000JPY
Other nclPrior1YearInstant15605000000JPY
Other nclCurrentQuarterInstant17042000000JPY
Noncurrent liabilitiesPrior1YearInstant32183000000JPY
Noncurrent liabilitiesCurrentQuarterInstant55519000000JPY
LiabilitiesPrior1YearInstant472372000000JPY
LiabilitiesCurrentQuarterInstant493358000000JPY
Capital stockPrior1YearInstant10649000000JPY
Capital stockCurrentQuarterInstant10649000000JPY
Capital surplusPrior1YearInstant49146000000JPY
Capital surplusCurrentQuarterInstant49146000000JPY
Retained earningsPrior1YearInstant191531000000JPY
Retained earningsCurrentQuarterInstant192005000000JPY
Treasury stockPrior1YearInstant-23107000000JPY
Treasury stockCurrentQuarterInstant-29108000000JPY
Shareholders equityPrior1YearInstant228219000000JPY
Shareholders equityCurrentQuarterInstant222693000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant18734000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant22443000000JPY
Revaluation reserve for landPrior1YearInstant-4276000000JPY
Revaluation reserve for landCurrentQuarterInstant-4276000000JPY
Valuation and translation adjustmentsPrior1YearInstant14458000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant18167000000JPY
Subscription rights to sharesPrior1YearInstant146000000JPY
Subscription rights to sharesCurrentQuarterInstant146000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass